Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Frank Martiniuk et al.|Clinical Cancer Research|2012Cited by 225
Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severitySai Zhang, M Snyder, Johnathan Cooper‐Knock et al.|Cell Systems|2022Cited by 37
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0